Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab Plus Cisplatin and Irinotecan in Refractory Esophageal and Gastric Cancer
NCT00397904Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Oct 2006
- Primary completion
- Sep 2010
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab in esophageal cancer, gastric cancer (GC), gastroesophageal junction cancer, sponsored by Memorial Sloan Kettering Cancer Center. Started Oct 2006; status: completed.
02
Drugs
cetuximab
03
Conditions
esophageal cancergastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT00397904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00397904.